CircuLex 14-3-3 Gamma ELISA Kit

The 14-3-3 proteins are cerebrospinal fluid (CSF) biomarkers of neuronal damage for infectious agents and other neurological disorders. Specifically, the gamma-isoform of the 14-3-3 protein is expressed in neurons and can be an indicator for neuronal damage in prion disease. Creutzfeldt–Jakob disease (CJD) is a prion disease leading to degenerative brain disorder manifesting as dementia and, in due course, death. Creutzfeldt-Jakob disease (CJD) is diagnosed based on symptoms as well as neuroimaging biomarkers, neurophysiological tests, and CSF biomarkers (14-3-3). An elevated risk for CJD is associated with 14-3-3 levels above 100,000 AU/mL and a probable diagnosis of CJD based on laboratory parameters above 50,000 AU/mL. Hence, 14-3-3 γ ELISA is the best biomarker for prion disease according to its sensitivity and specificity compared to western blots.

In addition to CJD diagnosis, 14-3-3 proteins were demonstrated in neuroaxonal of patients with COVID-19. A correlation of CSF 14-3-3 levels was observed in patients that progress to a long-standing neuro-COVID disease. Consequently, further studies of 14-3-3 levels are warranted as a prognostic biomarker for neuronal damage during early to late phases of COVID-19 infection.

MBLI offers a quantitative measurement of 14-3-3 Gamma (gamma isoform protein) in CSF, cell lysates in 14-3-3 Gamma ELISA Kit.